Breast Biomarker Cytology Practice in 2023: Results of a College of American Pathologists Survey.

Zaibo Li¹, Ann King², Rhona J Souers², Janie J Roberson³, Shahla Masood⁴, Deepu Alex⁵, Martin J Magers⁶, Poornima Hegde⁷, Sana O Tabbara⁸

¹From the Department of Pathology, The Ohio State University, Columbus (Li).

²Biostatistics, College of American Pathologists, Northfield, Illinois (King, Souers).

³the Department of Pathology, University of Alabama at Birmingham, Birmingham (Roberson).

⁴the Department of Pathology and Laboratory Medicine, University of Florida College of Medicine - Jacksonville, Jacksonville (Masood).

⁵Labcorp Drug Development, Indianapolis, Indiana (Alex).

⁶IHA Pathology and Laboratory Management, Ypsilanti, Michigan (Magers).

⁷the Department of Pathology and Laboratory Medicine, University of Connecticut, Farmington (Hegde).

⁸the Department of Pathology, Moffitt Cancer Center, Tampa, Florida (Tabbara).

PubMed DOI

Abstract

CONTEXT.—: The College of American Pathologists (CAP) surveys provide national benchmarks of pathology practice. OBJECTIVE.—: To investigate breast biomarker cytology practice in domestic and international laboratories in 2023. DESIGN.—: We analyzed data from the CAP Breast Biomarker Cytology Practice Supplemental Questionnaire that was distributed to laboratories participating in the 2023 CAP N…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.